Brain Enzyme Cuts Small Opioid Peptides Efficiently But Cannot Touch Large Ones
Brain alanyl aminopeptidase degraded leu-enkephalin 230× faster than dynorphin(1-17) — larger opioid peptides are naturally protected from this enzyme.
Quick Facts
What This Study Found
Brain alanyl aminopeptidase's efficiency drops dramatically with opioid peptide chain length. Dynorphin(1-17) acts as a competitive inhibitor rather than a substrate.
Key Numbers
How They Did This
Enzyme was purified to homogeneity from human cerebral cortex. Kinetic analysis measured cleavage rates for a series of leu-enkephalin-related peptides of increasing length.
Why This Research Matters
This explains why different opioid peptides last different amounts of time in the brain. Longer peptides like dynorphin resist breakdown, which affects how long their signals last.
The Bigger Picture
Peptide chain length is a natural defense against enzymatic degradation. This principle is directly applicable to designing longer-lasting therapeutic peptides.
What This Study Doesn't Tell Us
This was an in-vitro study with purified enzyme. In living brain tissue, multiple enzymes act simultaneously, so the actual breakdown pattern may differ.
Questions This Raises
- ?Could extending therapeutic peptides improve their half-life?
- ?Do longer endogenous opioid peptides have longer signaling duration?
Trust & Context
- Key Stat:
- 230× faster for short peptides Enkephalin (5 residues) vs dynorphin (17 residues) degradation rate
- Evidence Grade:
- Preliminary in-vitro study with purified human brain enzyme — clean kinetic data.
- Study Age:
- Published in 1989 — established chain length as a determinant of peptide stability.
- Original Title:
- Specificity of action of human brain alanyl aminopeptidase on Leu-enkephalin and dynorphin-related peptides.
- Published In:
- Neuropeptides, 13(4), 259-62 (1989)
- Authors:
- Gibson, A M, McDermott, J R, Lauffart, B, Mantle, D
- Database ID:
- RPEP-00113
Evidence Hierarchy
Frequently Asked Questions
Why do small peptides break down faster?
Enzymes can easily access and grip small peptides. Larger peptides physically block the enzyme active site, making cleavage difficult or impossible.
How does this help drug design?
Peptide drugs can be made longer or modified at their ends to resist enzymatic breakdown, extending their duration of action in the body.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00113APA
Gibson, A M; McDermott, J R; Lauffart, B; Mantle, D. (1989). Specificity of action of human brain alanyl aminopeptidase on Leu-enkephalin and dynorphin-related peptides.. Neuropeptides, 13(4), 259-62.
MLA
Gibson, A M, et al. "Specificity of action of human brain alanyl aminopeptidase on Leu-enkephalin and dynorphin-related peptides.." Neuropeptides, 1989.
RethinkPeptides
RethinkPeptides Research Database. "Specificity of action of human brain alanyl aminopeptidase o..." RPEP-00113. Retrieved from https://rethinkpeptides.com/research/gibson-1989-specificity-of-action-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.